Identification

Name
Ropinirole
Accession Number
DB00268  (APRD00302)
Type
Small Molecule
Groups
Approved, Investigational
Description

Ropinirole is a non-ergoline dopamine agonist, manufactured by GlaxoSmithKline. It is used in the treatment of Parkinson's disease, and is also one of two medications in the United States with an FDA-approved indication for the treatment of restless legs syndrome (the other being Pramipexole).

Structure
Thumb
Synonyms
  • Ropinirol
  • Ropinirolum
External IDs
SK&F 101468 / SK&F-101468
Product Ingredients
IngredientUNIICASInChI Key
Ropinirole HydrochlorideD7ZD41RZI991374-20-8XDXHAEQXIBQUEZ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act RopiniroleTablet1 mgOralActavis Pharma Company2009-07-22Not applicableCanada
Act RopiniroleTablet5 mgOralActavis Pharma Company2009-07-22Not applicableCanada
Act RopiniroleTablet0.25 mgOralActavis Pharma Company2009-07-22Not applicableCanada
Act RopiniroleTablet2 mgOralActavis Pharma Company2009-07-22Not applicableCanada
RequipTablet, film coated.25 mg/1OralGlaxosmithkline Inc1997-10-102019-01-31Us00007 4890 20 nlmimage10 cb18e587
RequipTablet, film coated2 mg/1OralGlaxosmithkline Inc1997-10-03Not applicableUs00007 4893 20 nlmimage10 d118e887
RequipTablet1 mgOralGlaxosmithkline Inc1997-09-25Not applicableCanada
RequipTablet, film coated3 mg/1OralGlaxosmithkline Inc2001-06-19Not applicableUs00007 4895 20 nlmimage10 d218e947
RequipTablet5 mgOralGlaxosmithkline Inc1997-09-25Not applicableCanada
RequipTablet, film coated1 mg/1OralGlaxosmithkline Inc1997-10-01Not applicableUs0007 489220180811 28838 zuoukn
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ropiniroleTablet1.0 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet3.0 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet0.5 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet5.0 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet2.0 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet0.25 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet4.0 mgOralApotex CorporationNot applicableNot applicableCanada
Dom-ropiniroleTablet2.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-ropiniroleTablet0.25 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-ropiniroleTablet1.0 mgOralDominion PharmacalNot applicableNot applicableCanada
International/Other Brands
Adartrel / ReQuip CR (GlaxoSmithKline) / Ronirol
Categories
UNII
030PYR8953
CAS number
91374-21-9
Weight
Average: 260.3746
Monoisotopic: 260.1888634
Chemical Formula
C16H24N2O
InChI Key
UHSKFQJFRQCDBE-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
IUPAC Name
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-one
SMILES
CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1

Pharmacology

Indication

For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.

Associated Conditions
Pharmacodynamics

Ropinirole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The mechanism of ropinirole-induced postural hypotension is presumed to be due to a D2 -mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance.

Mechanism of action

Ropinirole binds the dopamine receptors D3 and D2. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

TargetActionsOrganism
AD(3) dopamine receptor
agonist
Human
AD(2) dopamine receptor
agonist
Human
UD(4) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 1A
agonist
Human
U5-hydroxytryptamine receptor 1D
agonist
Human
U5-hydroxytryptamine receptor 2B
agonist
Human
UD(1A) dopamine receptor
agonist
Human
UD(1B) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 1B
agonist
Human
U5-hydroxytryptamine receptor 2A
agonist
Human
U5-hydroxytryptamine receptor 2C
agonist
Human
UAlpha-2A adrenergic receptor
agonist
Human
UAlpha-2B adrenergic receptor
agonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
Absorption

Absolute bioavailability is 55%, indicating a first pass effect. Food does not affect the extent of absorption.

Volume of distribution
  • 7.5 L/kg
  • 525 L
Protein binding

40% bound to plasma proteins with a blood-to-plasma ratio of 1:1.

Metabolism

Hepatic. Ropinirole is extensively metabolized to inactive metabolites via N -despropylation and hydroxylation pathways, largely by the P450 isoenzyme CYP1A2. N-despropyl ropinirole is the predominant metabolite found in urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%).

Route of elimination

Ropinirole is extensively metabolized by the liver to inactive metabolites, and less than 10% of the administered dose is excreted as unchanged drug in urine.

Half life

6 hours

Clearance
  • 47 L/hr [after oral administration to Parkinson's disease patients and patients with Restless Legs Syndrome]
Toxicity

Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the sedative activities of Ropinirole.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the sedative activities of Ropinirole.Experimental, Illicit
4-Methoxyamphetamine4-Methoxyamphetamine may increase the sedative activities of Ropinirole.Experimental, Illicit
7-Nitroindazole7-Nitroindazole may increase the sedative activities of Ropinirole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the sedative activities of Ropinirole.Experimental
AbirateroneThe serum concentration of Ropinirole can be increased when it is combined with Abiraterone.Approved
AcebutololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Acebutolol.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ropinirole.Approved, Investigational
AcepromazineAcepromazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
AceprometazineAceprometazine may increase the sedative activities of Ropinirole.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Ropinirole.Approved
AcetazolamideAcetazolamide may increase the sedative activities of Ropinirole.Approved, Vet Approved
AcetophenazineAcetophenazine may increase the sedative activities of Ropinirole.Approved
Acetylglycinamide chloral hydrateAcetylglycinamide chloral hydrate may increase the sedative activities of Ropinirole.Experimental
AdinazolamAdinazolam may increase the sedative activities of Ropinirole.Approved
AdipiplonAdipiplon may increase the sedative activities of Ropinirole.Investigational
AgomelatineAgomelatine may increase the sedative activities of Ropinirole.Approved, Investigational
AlaproclateAlaproclate may increase the sedative activities of Ropinirole.Experimental
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Ropinirole.Approved, Vet Approved
AlcuroniumAlcuronium may increase the sedative activities of Ropinirole.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Aldesleukin.Approved
AlfaxaloneAlfaxalone may increase the sedative activities of Ropinirole.Vet Approved
AlfentanilAlfentanil may increase the sedative activities of Ropinirole.Approved, Illicit
AlfuzosinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Ropinirole is combined with Aliskiren.Approved, Investigational
AllobarbitalAllobarbital may increase the sedative activities of Ropinirole.Experimental
AllopregnanoloneAllopregnanolone may increase the sedative activities of Ropinirole.Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Ropinirole.Approved, Withdrawn
AlphacetylmethadolAlphacetylmethadol may increase the sedative activities of Ropinirole.Experimental, Illicit
AlphaprodineAlphaprodine may increase the sedative activities of Ropinirole.Illicit
AlprazolamAlprazolam may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
AlprenololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Alprenolol.Approved, Withdrawn
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Ropinirole.Approved, Investigational
AmikacinAmikacin may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Amiloride.Approved
AmineptineAmineptine may increase the sedative activities of Ropinirole.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ropinirole.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Ropinirole.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Ropinirole.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Ropinirole.Approved, Investigational
AmitriptylineAmitriptyline may increase the sedative activities of Ropinirole.Approved
AmitriptylinoxideAmitriptylinoxide may increase the sedative activities of Ropinirole.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the sedative activities of Ropinirole.Approved, Illicit
AmoxapineAmoxapine may increase the sedative activities of Ropinirole.Approved
AmperozideAmperozide may increase the sedative activities of Ropinirole.Experimental
AmphetamineAmphetamine may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropinirole.Approved, Investigational
AmprenavirThe metabolism of Ropinirole can be decreased when combined with Amprenavir.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Ropinirole is combined with Amyl Nitrite.Approved
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Ropinirole.Approved
AniracetamAniracetam may increase the sedative activities of Ropinirole.Experimental
AnisodamineThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ropinirole.Approved, Investigational
ApalutamideThe serum concentration of Ropinirole can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Ropinirole.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Apraclonidine.Approved
ApramycinApramycin may increase the sedative activities of Ropinirole.Experimental, Vet Approved
AprepitantThe serum concentration of Ropinirole can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalAprobarbital may increase the sedative activities of Ropinirole.Approved, Illicit
ApronalideApronalide may increase the sedative activities of Ropinirole.Experimental
Arbaclofen PlacarbilArbaclofen Placarbil may increase the sedative activities of Ropinirole.Investigational
ArbekacinArbekacin may increase the sedative activities of Ropinirole.Approved, Investigational
AripiprazoleAripiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
Aripiprazole lauroxilAripiprazole lauroxil may increase the sedative activities of Ropinirole.Approved, Investigational
ArotinololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Arotinolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropinirole.Approved, Investigational
AsenapineAsenapine may increase the sedative activities of Ropinirole.Approved
AtazanavirThe metabolism of Ropinirole can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Atenolol.Approved
AtomoxetineAtomoxetine may increase the sedative activities of Ropinirole.Approved
AtracuriumAtracurium may increase the sedative activities of Ropinirole.Approved, Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the sedative activities of Ropinirole.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Ropinirole.Approved, Investigational
AzaperoneAzaperone may increase the sedative activities of Ropinirole.Investigational, Vet Approved
AZD-3043AZD-3043 may increase the sedative activities of Ropinirole.Investigational
AzelastineAzelastine may increase the sedative activities of Ropinirole.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Azilsartan medoxomil.Approved, Investigational
BaclofenBaclofen may increase the sedative activities of Ropinirole.Approved
BarbexacloneBarbexaclone may increase the sedative activities of Ropinirole.Experimental
BarbitalBarbital may increase the sedative activities of Ropinirole.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Ropinirole.Approved
BeclamideBeclamide may increase the sedative activities of Ropinirole.Experimental
BefunololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Befunolol.Experimental
BekanamycinBekanamycin may increase the sedative activities of Ropinirole.Experimental
BenactyzineBenactyzine may increase the sedative activities of Ropinirole.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the sedative activities of Ropinirole.Withdrawn
BenperidolBenperidol may increase the sedative activities of Ropinirole.Approved, Investigational
BenzoctamineBenzoctamine may increase the sedative activities of Ropinirole.Approved
BenzphetamineBenzphetamine may increase the sedative activities of Ropinirole.Approved, Illicit
BenzydamineThe metabolism of Benzydamine can be decreased when combined with Ropinirole.Approved
Benzyl alcoholBenzyl alcohol may increase the sedative activities of Ropinirole.Approved
Benzylpenicilloyl PolylysineRopinirole may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Ropinirole.Approved, Withdrawn
BetaxololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Betaxolol.Approved, Investigational
BevantololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Bevantolol.Approved
BicalutamideThe metabolism of Ropinirole can be decreased when combined with Bicalutamide.Approved
BifemelaneBifemelane may increase the sedative activities of Ropinirole.Experimental
BifeprunoxBifeprunox may increase the sedative activities of Ropinirole.Investigational
BisoprololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Bisoprolol.Approved
BL-1020BL-1020 may increase the sedative activities of Ropinirole.Investigational
BlonanserinBlonanserin may increase the sedative activities of Ropinirole.Approved, Investigational
BoceprevirThe metabolism of Ropinirole can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Ropinirole.Approved, Investigational
BosentanThe serum concentration of Ropinirole can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type ABotulinum Toxin Type A may increase the sedative activities of Ropinirole.Approved, Investigational
Botulinum Toxin Type BBotulinum Toxin Type B may increase the sedative activities of Ropinirole.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bretylium.Approved
BrexpiprazoleBrexpiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
BrimonidineBrimonidine may increase the sedative activities of Ropinirole.Approved
BrivaracetamBrivaracetam may increase the sedative activities of Ropinirole.Approved, Investigational
BrofaromineBrofaromine may increase the sedative activities of Ropinirole.Experimental
BromazepamBromazepam may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
BromisovalBromisoval may increase the sedative activities of Ropinirole.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved, Investigational
BromperidolBromperidol may increase the sedative activities of Ropinirole.Approved, Investigational
BrompheniramineBrompheniramine may increase the sedative activities of Ropinirole.Approved
BrotizolamBrotizolam may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
BucindololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Bucindolol.Investigational
BufotenineBufotenine may increase the sedative activities of Ropinirole.Experimental, Illicit
BufuralolThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bumetanide.Approved
BunazosinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Bunazosin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ropinirole.Approved, Investigational
BupranololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Bupranolol.Approved
BuprenorphineBuprenorphine may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational, Vet Approved
BupropionBupropion may increase the sedative activities of Ropinirole.Approved
BuspironeBuspirone may increase the sedative activities of Ropinirole.Approved, Investigational
ButabarbitalButabarbital may increase the sedative activities of Ropinirole.Approved, Illicit
ButalbitalButalbital may increase the sedative activities of Ropinirole.Approved, Illicit
ButaperazineButaperazine may increase the sedative activities of Ropinirole.Experimental
ButethalButethal may increase the sedative activities of Ropinirole.Approved, Illicit
ButorphanolButorphanol may increase the sedative activities of Ropinirole.Approved, Illicit, Vet Approved
ButriptylineButriptyline may increase the sedative activities of Ropinirole.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved
CaffeineThe metabolism of Ropinirole can be decreased when combined with Caffeine.Approved
CamazepamCamazepam may increase the sedative activities of Ropinirole.Approved, Illicit
CanagliflozinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Candesartan cilexetil.Approved
CannabidivarinCannabidivarin may increase the sedative activities of Ropinirole.Investigational
CapreomycinCapreomycin may increase the sedative activities of Ropinirole.Approved
CaptodiameCaptodiame may increase the sedative activities of Ropinirole.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Captopril.Approved
CarbamazepineCarbamazepine may increase the sedative activities of Ropinirole.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Ropinirole.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the sedative activities of Ropinirole.Approved
CarbromalCarbromal may increase the sedative activities of Ropinirole.Experimental
CarfentanilCarfentanil may increase the sedative activities of Ropinirole.Illicit, Investigational, Vet Approved
CariprazineCariprazine may increase the sedative activities of Ropinirole.Approved, Investigational
CarisbamateCarisbamate may increase the sedative activities of Ropinirole.Investigational
CarisoprodolCarisoprodol may increase the sedative activities of Ropinirole.Approved
CaroxazoneCaroxazone may increase the sedative activities of Ropinirole.Withdrawn
CarteololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Carteolol.Approved
CarvedilolThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Carvedilol.Approved, Investigational
CathinoneCathinone may increase the sedative activities of Ropinirole.Illicit
CeliprololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ropinirole can be increased when it is combined with Ceritinib.Approved
CetirizineCetirizine may increase the sedative activities of Ropinirole.Approved
Chloral hydrateChloral hydrate may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
ChlormezanoneChlormezanone may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
ChloroquineChloroquine may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Investigational, Withdrawn
ChlorphenamineChlorphenamine may increase the sedative activities of Ropinirole.Approved
ChlorphenesinChlorphenesin may increase the sedative activities of Ropinirole.Approved, Vet Approved, Withdrawn
ChlorproethazineChlorproethazine may increase the sedative activities of Ropinirole.Experimental
ChlorpromazineChlorpromazine may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
ChlorprothixeneChlorprothixene may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
ChlortetracyclineChlortetracycline may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Ropinirole is combined with Chlorthalidone.Approved
ChlorzoxazoneChlorzoxazone may increase the sedative activities of Ropinirole.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ropinirole.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Ropinirole.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Ropinirole.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ropinirole.Approved, Investigational
CinolazepamCinolazepam may increase the sedative activities of Ropinirole.Approved
CiprofloxacinThe serum concentration of Ropinirole can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Ropinirole.Approved, Investigational, Withdrawn
CisatracuriumCisatracurium may increase the sedative activities of Ropinirole.Approved
CitalopramCitalopram may increase the sedative activities of Ropinirole.Approved
ClarithromycinThe metabolism of Ropinirole can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the sedative activities of Ropinirole.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Clevidipine.Approved, Investigational
ClidiniumClidinium may increase the sedative activities of Ropinirole.Approved
ClindamycinClindamycin may increase the sedative activities of Ropinirole.Approved, Vet Approved
ClobazamClobazam may increase the sedative activities of Ropinirole.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Ropinirole.Approved, Investigational
clomethiazoleclomethiazole may increase the sedative activities of Ropinirole.Investigational
ClomipramineClomipramine may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
ClomocyclineClomocycline may increase the sedative activities of Ropinirole.Approved
ClonazepamClonazepam may increase the sedative activities of Ropinirole.Approved, Illicit
ClonidineClonidine may increase the sedative activities of Ropinirole.Approved
ClopenthixolClopenthixol may increase the sedative activities of Ropinirole.Experimental
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Ropinirole.Approved
CloranololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Cloranolol.Experimental
ClorazepateClorazepate may increase the sedative activities of Ropinirole.Approved, Illicit
ClothiapineClothiapine may increase the sedative activities of Ropinirole.Experimental
ClotiazepamClotiazepam may increase the sedative activities of Ropinirole.Approved, Illicit
ClotrimazoleThe metabolism of Ropinirole can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamCloxazolam may increase the sedative activities of Ropinirole.Approved, Investigational
ClozapineClozapine may increase the sedative activities of Ropinirole.Approved
CobicistatThe metabolism of Ropinirole can be decreased when combined with Cobicistat.Approved
CodeineCodeine may increase the sedative activities of Ropinirole.Approved, Illicit
ColistimethateColistimethate may increase the sedative activities of Ropinirole.Approved, Vet Approved
ColistinColistin may increase the sedative activities of Ropinirole.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ropinirole.Approved, Investigational
Conjugated estrogensConjugated estrogens may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
CrizotinibThe metabolism of Ropinirole can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Ropinirole can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineCyamemazine may increase the sedative activities of Ropinirole.Approved
CyclizineCyclizine may increase the sedative activities of Ropinirole.Approved
CyclobarbitalCyclobarbital may increase the sedative activities of Ropinirole.Experimental
CyclobenzaprineCyclobenzaprine may increase the sedative activities of Ropinirole.Approved
CyclopropaneCyclopropane may increase the sedative activities of Ropinirole.Experimental
CyclosporineCyclosporine may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the sedative activities of Ropinirole.Approved
Cyproterone acetateThe serum concentration of Ropinirole can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Ropinirole can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Ropinirole.Approved, Investigational
DanazolThe metabolism of Ropinirole can be decreased when combined with Danazol.Approved
DantroleneDantrolene may increase the sedative activities of Ropinirole.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Dapagliflozin.Approved
DapiprazoleDapiprazole may increase the sedative activities of Ropinirole.Approved
DapoxetineDapoxetine may increase the sedative activities of Ropinirole.Investigational
DarunavirThe metabolism of Ropinirole can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ropinirole can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolDeanol may increase the sedative activities of Ropinirole.Experimental
DecamethoniumDecamethonium may increase the sedative activities of Ropinirole.Approved
DeferasiroxThe serum concentration of Ropinirole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ropinirole can be decreased when combined with Delavirdine.Approved
DelorazepamDelorazepam may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
DemeclocyclineDemeclocycline may increase the sedative activities of Ropinirole.Approved
DeramciclaneDeramciclane may increase the sedative activities of Ropinirole.Investigational
DesfluraneDesflurane may increase the sedative activities of Ropinirole.Approved
DesipramineDesipramine may increase the sedative activities of Ropinirole.Approved, Investigational
DesloratadineDesloratadine may increase the sedative activities of Ropinirole.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the sedative activities of Ropinirole.Approved, Investigational
DetomidineDetomidine may increase the sedative activities of Ropinirole.Vet Approved
DexamethasoneThe serum concentration of Ropinirole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineDexbrompheniramine may increase the sedative activities of Ropinirole.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Ropinirole.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineDexmedetomidine may increase the sedative activities of Ropinirole.Approved, Vet Approved
DextofisopamDextofisopam may increase the sedative activities of Ropinirole.Investigational
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Ropinirole.Approved
DextromoramideDextromoramide may increase the sedative activities of Ropinirole.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the sedative activities of Ropinirole.Approved, Investigational
DiazepamDiazepam may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational, Vet Approved
DibekacinDibekacin may increase the sedative activities of Ropinirole.Experimental
DibenzepinDibenzepin may increase the sedative activities of Ropinirole.Experimental
DichloralphenazoneDichloralphenazone may increase the sedative activities of Ropinirole.Approved, Illicit
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ropinirole.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Ropinirole.Approved
DienestrolDienestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Diethyl etherDiethyl ether may increase the sedative activities of Ropinirole.Experimental
DiethylstilbestrolDiethylstilbestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DifenoxinDifenoxin may increase the sedative activities of Ropinirole.Approved, Illicit
DihydralazineThe metabolism of Dihydralazine can be decreased when combined with Ropinirole.Approved, Investigational
DihydrocodeineDihydrocodeine may increase the sedative activities of Ropinirole.Approved, Illicit
DihydroergocornineDihydroergocornine may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive and vasoconstricting activities of Ropinirole.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved, Investigational
DihydroetorphineDihydroetorphine may increase the sedative activities of Ropinirole.Experimental, Illicit
DihydromorphineDihydromorphine may increase the sedative activities of Ropinirole.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the sedative activities of Ropinirole.Investigational, Vet Approved
DiltiazemThe metabolism of Ropinirole can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateDimenhydrinate may increase the sedative activities of Ropinirole.Approved
DimetacrineDimetacrine may increase the sedative activities of Ropinirole.Approved, Withdrawn
DimethyltryptamineDimethyltryptamine may increase the sedative activities of Ropinirole.Experimental, Illicit
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Ropinirole.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Ropinirole is combined with Dinutuximab.Approved, Investigational
DiphenhydramineDiphenhydramine may increase the sedative activities of Ropinirole.Approved, Investigational
DiphenoxylateDiphenoxylate may increase the sedative activities of Ropinirole.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Dipyridamole.Approved
DixyrazineDixyrazine may increase the sedative activities of Ropinirole.Experimental
Domoic AcidDomoic Acid may increase the sedative activities of Ropinirole.Experimental
DomperidoneThe metabolism of Domperidone can be decreased when combined with Ropinirole.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the sedative activities of Ropinirole.Approved
DoramectinDoramectin may increase the sedative activities of Ropinirole.Vet Approved
DosulepinDosulepin may increase the sedative activities of Ropinirole.Approved
DotarizineDotarizine may increase the sedative activities of Ropinirole.Investigational
DoxacuriumDoxacurium may increase the sedative activities of Ropinirole.Approved
DoxazosinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Doxazosin.Approved
DoxefazepamDoxefazepam may increase the sedative activities of Ropinirole.Experimental
DoxepinDoxepin may increase the sedative activities of Ropinirole.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ropinirole.Approved, Investigational
DoxycyclineDoxycycline may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropinirole.Approved, Vet Approved
DPDPEDPDPE may increase the sedative activities of Ropinirole.Experimental
DronabinolDronabinol may increase the sedative activities of Ropinirole.Approved, Illicit
DronedaroneThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Dronedarone.Approved
DroperidolDroperidol may increase the sedative activities of Ropinirole.Approved, Vet Approved
DrotebanolDrotebanol may increase the sedative activities of Ropinirole.Experimental, Illicit
DroxidopaRopinirole may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the sedative activities of Ropinirole.Approved
DyclonineDyclonine may increase the sedative activities of Ropinirole.Approved
EcopipamEcopipam may increase the sedative activities of Ropinirole.Investigational
EdivoxetineEdivoxetine may increase the sedative activities of Ropinirole.Investigational
EfavirenzEfavirenz may increase the sedative activities of Ropinirole.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ropinirole.Approved, Investigational
ElagolixThe metabolism of Elagolix can be decreased when combined with Ropinirole.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Ropinirole.Approved
EltanoloneEltanolone may increase the sedative activities of Ropinirole.Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Ropinirole.Approved
EmeproniumEmepronium may increase the sedative activities of Ropinirole.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.Approved
EmylcamateEmylcamate may increase the sedative activities of Ropinirole.Experimental
EnalaprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropinirole.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Ropinirole.Approved, Investigational
EnfluraneEnflurane may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
EnoxacinThe metabolism of Ropinirole can be decreased when combined with Enoxacin.Approved, Investigational
EntacaponeEntacapone may increase the sedative activities of Ropinirole.Approved, Investigational
EnzalutamideThe serum concentration of Ropinirole can be decreased when it is combined with Enzalutamide.Approved
EpanololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Epanolol.Experimental
EperisoneEperisone may increase the sedative activities of Ropinirole.Approved, Investigational
EpimestrolEpimestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Ropinirole is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropinirole.Approved
EprosartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Eprosartan.Approved
EquolEquol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Investigational
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Ropinirole.Approved, Investigational
ErythromycinThe metabolism of Ropinirole can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Esatenolol.Experimental
EscitalopramEscitalopram may increase the sedative activities of Ropinirole.Approved, Investigational
EslicarbazepineEslicarbazepine may increase the sedative activities of Ropinirole.Approved
Eslicarbazepine acetateEslicarbazepine acetate may increase the sedative activities of Ropinirole.Approved
EsmirtazapineEsmirtazapine may increase the sedative activities of Ropinirole.Investigational
EsmololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Esmolol.Approved
EsreboxetineEsreboxetine may increase the sedative activities of Ropinirole.Investigational
EstazolamEstazolam may increase the sedative activities of Ropinirole.Approved, Illicit
EstradiolEstradiol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
Estradiol benzoateEstradiol benzoate may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Ropinirole.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
EstriolEstriol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
EstroneEstrone may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
Estrone sulfateEstrone sulfate may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
EszopicloneEszopiclone may increase the sedative activities of Ropinirole.Approved, Investigational
Etacrynic acidEtacrynic acid may increase the sedative activities of Ropinirole.Approved, Investigational
EthadioneEthadione may increase the sedative activities of Ropinirole.Experimental
EthchlorvynolEthchlorvynol may increase the sedative activities of Ropinirole.Approved, Illicit, Withdrawn
Ethinyl EstradiolEthinyl Estradiol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
EthosuximideEthosuximide may increase the sedative activities of Ropinirole.Approved
EthotoinEthotoin may increase the sedative activities of Ropinirole.Approved
Ethyl carbamateEthyl carbamate may increase the sedative activities of Ropinirole.Withdrawn
Ethyl chlorideEthyl chloride may increase the sedative activities of Ropinirole.Approved, Experimental, Investigational
Ethyl loflazepateEthyl loflazepate may increase the sedative activities of Ropinirole.Approved, Illicit
EthylmorphineEthylmorphine may increase the sedative activities of Ropinirole.Approved, Illicit
EtifoxineEtifoxine may increase the sedative activities of Ropinirole.Investigational, Withdrawn
EtiracetamEtiracetam may increase the sedative activities of Ropinirole.Investigational
EtizolamEtizolam may increase the sedative activities of Ropinirole.Approved
EtomidateEtomidate may increase the sedative activities of Ropinirole.Approved
EtoperidoneEtoperidone may increase the sedative activities of Ropinirole.Withdrawn
EtoposideThe metabolism of Etoposide can be decreased when combined with Ropinirole.Approved
EtorphineEtorphine may increase the sedative activities of Ropinirole.Illicit, Vet Approved
EtravirineThe serum concentration of Ropinirole can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the sedative activities of Ropinirole.Approved, Investigational
FabomotizoleFabomotizole may increase the sedative activities of Ropinirole.Experimental
Fazadinium bromideFazadinium bromide may increase the sedative activities of Ropinirole.Experimental
FebarbamateFebarbamate may increase the sedative activities of Ropinirole.Experimental
FelbamateFelbamate may increase the sedative activities of Ropinirole.Approved
FelodipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine.Approved, Investigational
FencamfamineFencamfamine may increase the sedative activities of Ropinirole.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropinirole.Approved
FentanylFentanyl may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational, Vet Approved
FenyramidolFenyramidol may increase the sedative activities of Ropinirole.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ropinirole.Approved
FexofenadineFexofenadine may increase the sedative activities of Ropinirole.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ropinirole.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Ropinirole.Approved, Withdrawn
FlibanserinFlibanserin may increase the sedative activities of Ropinirole.Approved, Investigational
FluanisoneFluanisone may increase the sedative activities of Ropinirole.Experimental
FluconazoleThe metabolism of Ropinirole can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamFludiazepam may increase the sedative activities of Ropinirole.Approved, Illicit
FlunarizineFlunarizine may increase the sedative activities of Ropinirole.Approved
FlunitrazepamFlunitrazepam may increase the sedative activities of Ropinirole.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Ropinirole.Approved
FluoxetineFluoxetine may increase the sedative activities of Ropinirole.Approved, Vet Approved
FlupentixolFlupentixol may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the sedative activities of Ropinirole.Approved
FlurazepamFlurazepam may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
FluspirileneFluspirilene may increase the sedative activities of Ropinirole.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Ropinirole.Approved, Investigational
Fluticasone propionateFluticasone propionate may increase the sedative activities of Ropinirole.Approved
FluvoxamineFluvoxamine may increase the sedative activities of Ropinirole.Approved, Investigational
FosamprenavirThe metabolism of Ropinirole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ropinirole can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Fosinopril.Approved
FosphenytoinFosphenytoin may increase the sedative activities of Ropinirole.Approved, Investigational
FospropofolFospropofol may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
FramycetinFramycetin may increase the sedative activities of Ropinirole.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Ropinirole.Approved, Investigational
FurazolidoneFurazolidone may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ropinirole can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinGabapentin may increase the sedative activities of Ropinirole.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the sedative activities of Ropinirole.Approved, Investigational
GaboxadolGaboxadol may increase the sedative activities of Ropinirole.Investigational
GallamineGallamine may increase the sedative activities of Ropinirole.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the sedative activities of Ropinirole.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
Gantacurium ChlorideGantacurium Chloride may increase the sedative activities of Ropinirole.Investigational
GedocarnilGedocarnil may increase the sedative activities of Ropinirole.Experimental
GeneticinGeneticin may increase the sedative activities of Ropinirole.Experimental
GenisteinThe metabolism of Genistein can be decreased when combined with Ropinirole.Investigational
GentamicinGentamicin may increase the sedative activities of Ropinirole.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the sedative activities of Ropinirole.Experimental
GepironeGepirone may increase the sedative activities of Ropinirole.Investigational
GlutethimideGlutethimide may increase the sedative activities of Ropinirole.Approved, Illicit
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Ropinirole.Approved, Investigational, Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Ropinirole.Approved, Investigational
GuanfacineGuanfacine may increase the sedative activities of Ropinirole.Approved, Investigational
HalazepamHalazepam may increase the sedative activities of Ropinirole.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the sedative activities of Ropinirole.Approved
HalothaneHalothane may increase the sedative activities of Ropinirole.Approved, Vet Approved
HarmalineHarmaline may increase the sedative activities of Ropinirole.Experimental
HeptabarbitalHeptabarbital may increase the sedative activities of Ropinirole.Approved
HeroinHeroin may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
HexafluroniumHexafluronium may increase the sedative activities of Ropinirole.Approved
HexamethoniumHexamethonium may increase the sedative activities of Ropinirole.Experimental
HexapropymateHexapropymate may increase the sedative activities of Ropinirole.Experimental
HexestrolHexestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Withdrawn
HexobarbitalHexobarbital may increase the sedative activities of Ropinirole.Approved
HydracarbazineHydracarbazine may increase the sedative activities of Ropinirole.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneRopinirole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ropinirole.Approved, Investigational
HydromorphoneHydromorphone may increase the sedative activities of Ropinirole.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ropinirole.Approved
Hygromycin BHygromycin B may increase the sedative activities of Ropinirole.Vet Approved
HypericinHypericin may increase the sedative activities of Ropinirole.Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Ropinirole.Approved
IdelalisibThe metabolism of Ropinirole can be decreased when combined with Idelalisib.Approved
IfenprodilIfenprodil may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
IloperidoneIloperidone may increase the sedative activities of Ropinirole.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Ropinirole.Approved, Investigational
ImagabalinImagabalin may increase the sedative activities of Ropinirole.Investigational
ImatinibThe metabolism of Ropinirole can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Ropinirole.Investigational
ImipramineImipramine may increase the sedative activities of Ropinirole.Approved
Imipramine oxideImipramine oxide may increase the sedative activities of Ropinirole.Experimental
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Ropinirole.Approved, Investigational
IndalpineIndalpine may increase the sedative activities of Ropinirole.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Indapamide.Approved
IndenololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Indenolol.Withdrawn
IndinavirThe metabolism of Ropinirole can be decreased when combined with Indinavir.Approved
IndiplonIndiplon may increase the sedative activities of Ropinirole.Investigational
IndoraminThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Indoramin.Withdrawn
IprindoleIprindole may increase the sedative activities of Ropinirole.Experimental
IproclozideIproclozide may increase the sedative activities of Ropinirole.Withdrawn
IproniazidIproniazid may increase the sedative activities of Ropinirole.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Ropinirole can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Ropinirole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinIsepamicin may increase the sedative activities of Ropinirole.Experimental
IsocarboxazidIsocarboxazid may increase the sedative activities of Ropinirole.Approved
IsofluraneIsoflurane may increase the sedative activities of Ropinirole.Approved, Vet Approved
IsoniazidThe metabolism of Ropinirole can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Ropinirole can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ropinirole can be increased when it is combined with Ivacaftor.Approved
KanamycinKanamycin may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
KetamineKetamine may increase the sedative activities of Ropinirole.Approved, Vet Approved
KetazolamKetazolam may increase the sedative activities of Ropinirole.Approved
KetobemidoneKetobemidone may increase the sedative activities of Ropinirole.Approved, Investigational
KetoconazoleThe metabolism of Ropinirole can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the sedative activities of Ropinirole.Approved, Nutraceutical, Withdrawn
LabetalolThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Labetalol.Approved
LacidipineRopinirole may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideLacosamide may increase the sedative activities of Ropinirole.Approved
LamotrigineLamotrigine may increase the sedative activities of Ropinirole.Approved, Investigational
LandiololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Landiolol.Investigational
LanicemineLanicemine may increase the sedative activities of Ropinirole.Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropinirole.Approved, Investigational
LevetiracetamLevetiracetam may increase the sedative activities of Ropinirole.Approved, Investigational
LevobetaxololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Levobetaxolol.Approved, Investigational
LevobunololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ropinirole.Approved, Investigational
LevocabastineLevocabastine may increase the sedative activities of Ropinirole.Approved, Investigational
LevocetirizineLevocetirizine may increase the sedative activities of Ropinirole.Approved
LevodopaLevodopa may increase the sedative activities of Ropinirole.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the sedative activities of Ropinirole.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the sedative activities of Ropinirole.Approved, Investigational
LevorphanolLevorphanol may increase the sedative activities of Ropinirole.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Ropinirole.Approved, Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Ropinirole.Approved, Vet Approved
LincomycinLincomycin may increase the sedative activities of Ropinirole.Approved, Vet Approved
LinezolidLinezolid may increase the sedative activities of Ropinirole.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Lisinopril.Approved, Investigational
LisurideLisuride may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved, Investigational
Lithium carbonateLithium carbonate may increase the sedative activities of Ropinirole.Approved
Lithium cationLithium cation may increase the sedative activities of Ropinirole.Experimental
LobeglitazoneThe metabolism of Ropinirole can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilLofentanil may increase the sedative activities of Ropinirole.Illicit
LofepramineLofepramine may increase the sedative activities of Ropinirole.Experimental
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Ropinirole.Approved, Investigational
LopinavirThe metabolism of Ropinirole can be decreased when combined with Lopinavir.Approved
LoprazolamLoprazolam may increase the sedative activities of Ropinirole.Experimental
LoratadineLoratadine may increase the sedative activities of Ropinirole.Approved, Investigational
LorazepamLorazepam may increase the sedative activities of Ropinirole.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Ropinirole.Approved
LormetazepamLormetazepam may increase the sedative activities of Ropinirole.Approved
LorpiprazoleThe serum concentration of Ropinirole can be increased when it is combined with Lorpiprazole.Approved
LortalamineLortalamine may increase the sedative activities of Ropinirole.Experimental
LosartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Losartan.Approved
LovastatinThe metabolism of Ropinirole can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the sedative activities of Ropinirole.Approved
LuliconazoleThe serum concentration of Ropinirole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ropinirole can be increased when combined with Lumacaftor.Approved
LumateperoneLumateperone may increase the sedative activities of Ropinirole.Investigational
LurasidoneLurasidone may increase the sedative activities of Ropinirole.Approved, Investigational
LymecyclineLymecycline may increase the sedative activities of Ropinirole.Approved, Investigational
Magnesium acetateMagnesium acetate may increase the sedative activities of Ropinirole.Approved
Magnesium acetate tetrahydrateMagnesium acetate tetrahydrate may increase the sedative activities of Ropinirole.Approved
Magnesium Aluminum SilicateMagnesium Aluminum Silicate may increase the sedative activities of Ropinirole.Approved
Magnesium aspartateMagnesium aspartate may increase the sedative activities of Ropinirole.Experimental
Magnesium carbonateMagnesium carbonate may increase the sedative activities of Ropinirole.Approved, Investigational
Magnesium cationMagnesium cation may increase the sedative activities of Ropinirole.Approved, Nutraceutical
Magnesium chlorideMagnesium chloride may increase the sedative activities of Ropinirole.Approved
Magnesium citrateMagnesium citrate may increase the sedative activities of Ropinirole.Approved
Magnesium gluconateMagnesium gluconate may increase the sedative activities of Ropinirole.Approved, Investigational
Magnesium glycinateMagnesium glycinate may increase the sedative activities of Ropinirole.Approved
Magnesium hydroxideMagnesium hydroxide may increase the sedative activities of Ropinirole.Approved, Investigational
Magnesium orotateMagnesium orotate may increase the sedative activities of Ropinirole.Experimental
Magnesium oxideMagnesium oxide may increase the sedative activities of Ropinirole.Approved
Magnesium phosphateMagnesium phosphate may increase the sedative activities of Ropinirole.Experimental
Magnesium silicateMagnesium silicate may increase the sedative activities of Ropinirole.Approved
Magnesium stearateMagnesium stearate may increase the sedative activities of Ropinirole.Investigational
Magnesium sulfateThe therapeutic efficacy of Ropinirole can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate may increase the sedative activities of Ropinirole.Approved
MannitolThe risk or severity of adverse effects can be increased when Ropinirole is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the sedative activities of Ropinirole.Approved, Investigational
MazindolMazindol may increase the sedative activities of Ropinirole.Approved, Investigational
MebanazineMebanazine may increase the sedative activities of Ropinirole.Withdrawn
MebicarMebicar may increase the sedative activities of Ropinirole.Experimental
MebutamateMebutamate may increase the sedative activities of Ropinirole.Approved
MecamylamineMecamylamine may increase the sedative activities of Ropinirole.Approved, Investigational
MeclizineMeclizine may increase the sedative activities of Ropinirole.Approved
MedazepamMedazepam may increase the sedative activities of Ropinirole.Experimental
MedetomidineMedetomidine may increase the sedative activities of Ropinirole.Vet Approved
MedifoxamineMedifoxamine may increase the sedative activities of Ropinirole.Experimental
MelatoninMelatonin may increase the sedative activities of Ropinirole.Approved, Nutraceutical, Vet Approved
MelitracenMelitracen may increase the sedative activities of Ropinirole.Experimental, Investigational
MelperoneMelperone may increase the sedative activities of Ropinirole.Approved, Investigational
MephenesinMephenesin may increase the sedative activities of Ropinirole.Approved
MephenoxaloneMephenoxalone may increase the sedative activities of Ropinirole.Experimental
MephenytoinMephenytoin may increase the sedative activities of Ropinirole.Investigational, Withdrawn
MepindololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Mepindolol.Experimental
MeprobamateMeprobamate may increase the sedative activities of Ropinirole.Approved, Illicit
MeptazinolMeptazinol may increase the sedative activities of Ropinirole.Experimental
MesoridazineMesoridazine may increase the sedative activities of Ropinirole.Approved, Investigational
MestranolMestranol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
MetaxaloneMetaxalone may increase the sedative activities of Ropinirole.Approved
MetergolineMetergoline may increase the hypertensive and vasoconstricting activities of Ropinirole.Experimental
MethacyclineMethacycline may increase the sedative activities of Ropinirole.Approved, Investigational
MethadoneMethadone may increase the sedative activities of Ropinirole.Approved
Methadyl AcetateMethadyl Acetate may increase the sedative activities of Ropinirole.Approved, Illicit
MethallenestrilMethallenestril may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Experimental
MethamphetamineMethamphetamine may increase the sedative activities of Ropinirole.Approved, Illicit
MethapyrileneMethapyrilene may increase the sedative activities of Ropinirole.Withdrawn
MethaqualoneMethaqualone may increase the sedative activities of Ropinirole.Illicit, Withdrawn
MetharbitalMetharbital may increase the sedative activities of Ropinirole.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Methazolamide.Approved
MethocarbamolMethocarbamol may increase the sedative activities of Ropinirole.Approved, Vet Approved
MethohexitalMethohexital may increase the sedative activities of Ropinirole.Approved
MethotrimeprazineMethotrimeprazine may increase the sedative activities of Ropinirole.Approved, Investigational
MethoxyfluraneMethoxyflurane may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
MethsuximideMethsuximide may increase the sedative activities of Ropinirole.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Ropinirole is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the sedative activities of Ropinirole.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved
MethylpentynolMethylpentynol may increase the sedative activities of Ropinirole.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the sedative activities of Ropinirole.Approved
MethyprylonMethyprylon may increase the sedative activities of Ropinirole.Approved, Illicit, Withdrawn
MethysergideMethysergide may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved
MetipranololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Metipranolol.Approved
MetoclopramideThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetocurineMetocurine may increase the sedative activities of Ropinirole.Approved
Metocurine IodideMetocurine Iodide may increase the sedative activities of Ropinirole.Approved, Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Ropinirole is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ropinirole.Approved, Investigational
MexiletineThe metabolism of Mexiletine can be decreased when combined with Ropinirole.Approved, Investigational
MianserinMianserin may increase the sedative activities of Ropinirole.Approved, Investigational
MibefradilThe metabolism of Ropinirole can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Ropinirole can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinMicronomicin may increase the sedative activities of Ropinirole.Experimental
MidazolamMidazolam may increase the sedative activities of Ropinirole.Approved, Illicit
MidomafetamineMidomafetamine may increase the sedative activities of Ropinirole.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Ropinirole can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Ropinirole can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the sedative activities of Ropinirole.Approved, Investigational
MinaprineMinaprine may increase the sedative activities of Ropinirole.Approved
MinocyclineMinocycline may increase the sedative activities of Ropinirole.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Minoxidil.Approved, Investigational
MirtazapineMirtazapine may increase the sedative activities of Ropinirole.Approved
MitotaneThe serum concentration of Ropinirole can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the sedative activities of Ropinirole.Approved
MoclobemideMoclobemide may increase the sedative activities of Ropinirole.Approved, Investigational
ModafinilThe serum concentration of Ropinirole can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Moexipril.Approved
MolindoneMolindone may increase the sedative activities of Ropinirole.Approved
MoperoneMoperone may increase the sedative activities of Ropinirole.Experimental
MoricizineMoricizine may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
MorphineMorphine may increase the sedative activities of Ropinirole.Approved, Investigational
MosapramineMosapramine may increase the sedative activities of Ropinirole.Experimental
MoxestrolMoxestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Experimental
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Ropinirole.Approved, Investigational
MRK-409MRK-409 may increase the sedative activities of Ropinirole.Experimental
NabiloneNabilone may increase the sedative activities of Ropinirole.Approved, Investigational
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Ropinirole.Approved
NadololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Nadolol.Approved
NafcillinThe serum concentration of Ropinirole can be decreased when it is combined with Nafcillin.Approved, Investigational
NalbuphineNalbuphine may increase the sedative activities of Ropinirole.Approved
NaloxoneThe metabolism of Ropinirole can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Ropinirole.Approved, Vet Approved
NeamineNeamine may increase the sedative activities of Ropinirole.Experimental
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Ropinirole.Approved, Investigational
NefazodoneNefazodone may increase the sedative activities of Ropinirole.Approved, Withdrawn
NefiracetamNefiracetam may increase the sedative activities of Ropinirole.Investigational
NelfinavirThe metabolism of Ropinirole can be decreased when combined with Nelfinavir.Approved
NeocitrullamonNeocitrullamon may increase the sedative activities of Ropinirole.Experimental
NeomycinNeomycin may increase the sedative activities of Ropinirole.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the sedative activities of Ropinirole.Investigational
NesiritideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nesiritide.Approved, Investigational
NetilmicinNetilmicin may increase the sedative activities of Ropinirole.Approved, Investigational
NetupitantThe serum concentration of Ropinirole can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Ropinirole can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the sedative activities of Ropinirole.Withdrawn
NiaprazineNiaprazine may increase the sedative activities of Ropinirole.Experimental
NicardipineThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Ropinirole.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Ropinirole.Approved
NifedipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Niguldipine.Experimental
NilotinibThe metabolism of Ropinirole can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Ropinirole.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nisoldipine.Approved
NisoxetineNisoxetine may increase the sedative activities of Ropinirole.Experimental
NitrazepamNitrazepam may increase the sedative activities of Ropinirole.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Ropinirole.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nitrous acid.Approved, Investigational
Nitrous oxideNitrous oxide may increase the sedative activities of Ropinirole.Approved, Vet Approved
NomifensineNomifensine may increase the sedative activities of Ropinirole.Withdrawn
NordazepamNordazepam may increase the sedative activities of Ropinirole.Approved
NormethadoneNormethadone may increase the sedative activities of Ropinirole.Approved, Illicit
NortriptylineNortriptyline may increase the sedative activities of Ropinirole.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropinirole.Approved, Investigational
OctamoxinOctamoxin may increase the sedative activities of Ropinirole.Withdrawn
OlanzapineOlanzapine may increase the sedative activities of Ropinirole.Approved, Investigational
OlaparibThe metabolism of Ropinirole can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the sedative activities of Ropinirole.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ropinirole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the sedative activities of Ropinirole.Approved
OpipramolOpipramol may increase the sedative activities of Ropinirole.Investigational
OpiumOpium may increase the sedative activities of Ropinirole.Approved, Illicit
OrphenadrineOrphenadrine may increase the sedative activities of Ropinirole.Approved
OrvepitantOrvepitant may increase the sedative activities of Ropinirole.Investigational
OsanetantOsanetant may increase the sedative activities of Ropinirole.Investigational
OsimertinibThe serum concentration of Ropinirole can be increased when it is combined with Osimertinib.Approved
OxaflozaneOxaflozane may increase the sedative activities of Ropinirole.Experimental
OxaprotilineOxaprotiline may increase the sedative activities of Ropinirole.Experimental
OxazepamOxazepam may increase the sedative activities of Ropinirole.Approved
OxcarbazepineOxcarbazepine may increase the sedative activities of Ropinirole.Approved
OxiracetamOxiracetam may increase the sedative activities of Ropinirole.Experimental
OxitriptanOxitriptan may increase the sedative activities of Ropinirole.Approved, Investigational, Nutraceutical
OxprenololOxprenolol may increase the sedative activities of Ropinirole.Approved
OxycodoneOxycodone may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
OxypertineOxypertine may increase the sedative activities of Ropinirole.Experimental
OxytetracyclineOxytetracycline may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropinirole.Approved, Vet Approved
PalbociclibThe serum concentration of Ropinirole can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidonePaliperidone may increase the sedative activities of Ropinirole.Approved
PancuroniumPancuronium may increase the sedative activities of Ropinirole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Papaverine.Approved, Investigational
ParaldehydeParaldehyde may increase the sedative activities of Ropinirole.Approved, Investigational
ParamethadioneParamethadione may increase the sedative activities of Ropinirole.Approved
PargylinePargyline may increase the sedative activities of Ropinirole.Approved
ParomomycinParomomycin may increase the sedative activities of Ropinirole.Approved, Investigational
ParoxetineParoxetine may increase the sedative activities of Ropinirole.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Ropinirole.Approved
PefloxacinThe metabolism of Pefloxacin can be decreased when combined with Ropinirole.Approved
Peginterferon alfa-2bThe serum concentration of Ropinirole can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Penbutolol.Approved, Investigational
PenfluridolPenfluridol may increase the sedative activities of Ropinirole.Experimental
PenimepicyclinePenimepicycline may increase the sedative activities of Ropinirole.Experimental
PentazocinePentazocine may increase the sedative activities of Ropinirole.Approved, Vet Approved
PentobarbitalPentobarbital may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Ropinirole.Approved, Investigational
PerampanelPerampanel may increase the sedative activities of Ropinirole.Approved
PerazinePerazine may increase the sedative activities of Ropinirole.Approved, Investigational
PergolidePergolide may increase the hypertensive and vasoconstricting activities of Ropinirole.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Perindopril.Approved
PerospironePerospirone may increase the sedative activities of Ropinirole.Approved
PerphenazinePerphenazine may increase the sedative activities of Ropinirole.Approved
PethidinePethidine may increase the sedative activities of Ropinirole.Approved
PhenacemidePhenacemide may increase the sedative activities of Ropinirole.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ropinirole.Withdrawn
PhenazocinePhenazocine may increase the sedative activities of Ropinirole.Experimental
PhencyclidinePhencyclidine may increase the sedative activities of Ropinirole.Illicit
PhenelzinePhenelzine may increase the sedative activities of Ropinirole.Approved
PhenethylaminePhenethylamine may increase the sedative activities of Ropinirole.Experimental
PheneturidePheneturide may increase the sedative activities of Ropinirole.Experimental
PhenibutPhenibut may increase the sedative activities of Ropinirole.Experimental
PheniprazinePheniprazine may increase the sedative activities of Ropinirole.Withdrawn
PhenobarbitalPhenobarbital may increase the sedative activities of Ropinirole.Approved, Investigational
PhenoperidinePhenoperidine may increase the sedative activities of Ropinirole.Experimental
PhenoxybenzamineThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the sedative activities of Ropinirole.Withdrawn
PhenprobamatePhenprobamate may increase the sedative activities of Ropinirole.Experimental
PhensuximidePhensuximide may increase the sedative activities of Ropinirole.Approved
PhentolamineThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Phentolamine.Approved
PhenytoinPhenytoin may increase the sedative activities of Ropinirole.Approved, Vet Approved
PimavanserinPimavanserin may increase the sedative activities of Ropinirole.Approved, Investigational
PimobendanThe metabolism of Pimobendan can be decreased when combined with Ropinirole.Vet Approved
PimozidePimozide may increase the sedative activities of Ropinirole.Approved
PinazepamPinazepam may increase the sedative activities of Ropinirole.Experimental
PindololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Pindolol.Approved, Investigational
PipamperonePipamperone may increase the sedative activities of Ropinirole.Approved, Investigational
PipecuroniumPipecuronium may increase the sedative activities of Ropinirole.Approved
Pipemidic acidThe metabolism of Pipemidic acid can be decreased when combined with Ropinirole.Experimental
PipotiazinePipotiazine may increase the sedative activities of Ropinirole.Approved, Investigational
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Ropinirole.Approved, Investigational
PiritramidePiritramide may increase the sedative activities of Ropinirole.Approved, Investigational
PirlimycinPirlimycin may increase the sedative activities of Ropinirole.Vet Approved
PirlindolePirlindole may increase the sedative activities of Ropinirole.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Ropinirole.Approved, Investigational
PivagabinePivagabine may increase the sedative activities of Ropinirole.Investigational
PivhydrazinePivhydrazine may increase the sedative activities of Ropinirole.Withdrawn
PizotifenPizotifen may increase the sedative activities of Ropinirole.Approved
PlazomicinPlazomicin may increase the sedative activities of Ropinirole.Approved, Investigational
Polyestradiol phosphatePolyestradiol phosphate may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
Polymyxin B SulfatePolymyxin B Sulfate may increase the sedative activities of Ropinirole.Approved, Vet Approved
PomalidomidePomalidomide may increase the sedative activities of Ropinirole.Approved
PosaconazoleThe metabolism of Ropinirole can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Practolol.Approved
PramipexoleRopinirole may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamPrazepam may increase the sedative activities of Ropinirole.Approved, Illicit
PrazosinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Prazosin.Approved
PregabalinPregabalin may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
PridinolPridinol may increase the sedative activities of Ropinirole.Experimental
PrimidonePrimidone may increase the sedative activities of Ropinirole.Approved, Vet Approved
ProcainamideProcainamide may increase the sedative activities of Ropinirole.Approved
ProcaineProcaine may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the sedative activities of Ropinirole.Approved, Investigational
ProchlorperazineProchlorperazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
ProgabideProgabide may increase the sedative activities of Ropinirole.Approved, Investigational
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Ropinirole.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Ropinirole.Approved
PromazinePromazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
PromestrienePromestriene may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Investigational
PromethazinePromethazine may increase the sedative activities of Ropinirole.Approved, Investigational
PropafenoneThe serum concentration of Ropinirole can be increased when it is combined with Propafenone.Approved
PropanididPropanidid may increase the sedative activities of Ropinirole.Experimental
PropericiazinePropericiazine may increase the sedative activities of Ropinirole.Approved, Investigational
PropiomazinePropiomazine may increase the sedative activities of Ropinirole.Approved
PropiopromazinePropiopromazine may increase the sedative activities of Ropinirole.Vet Approved
PropiverineThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Propiverine.Approved, Investigational
PropofolPropofol may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
PropranololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Propranolol.Approved, Investigational
ProthipendylProthipendyl may increase the sedative activities of Ropinirole.Investigational
ProtriptylineProtriptyline may increase the sedative activities of Ropinirole.Approved
ProxibarbalProxibarbal may increase the sedative activities of Ropinirole.Experimental
PseudoephedrinePseudoephedrine may increase the sedative activities of Ropinirole.Approved
PsilocybinePsilocybine may increase the sedative activities of Ropinirole.Investigational
PuromycinPuromycin may increase the sedative activities of Ropinirole.Experimental
PyrantelPyrantel may increase the sedative activities of Ropinirole.Approved, Vet Approved
PyrithyldionePyrithyldione may increase the sedative activities of Ropinirole.Experimental
QuazepamQuazepam may increase the sedative activities of Ropinirole.Approved, Illicit
QuetiapineQuetiapine may increase the sedative activities of Ropinirole.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Quinapril.Approved, Investigational
QuinestrolQuinestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
QuinidineQuinidine may increase the sedative activities of Ropinirole.Approved, Investigational
QuinineQuinine may increase the sedative activities of Ropinirole.Approved
QuinupramineQuinupramine may increase the sedative activities of Ropinirole.Experimental
RacloprideRaclopride may increase the sedative activities of Ropinirole.Investigational
RamelteonRamelteon may increase the sedative activities of Ropinirole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Ramipril.Approved
RamosetronThe metabolism of Ramosetron can be decreased when combined with Ropinirole.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Ropinirole.Approved
RapacuroniumRapacuronium may increase the sedative activities of Ropinirole.Withdrawn
RasagilineRasagiline may increase the sedative activities of Ropinirole.Approved
ReboxetineReboxetine may increase the sedative activities of Ropinirole.Approved, Investigational
RemacemideRemacemide may increase the sedative activities of Ropinirole.Investigational
RemifentanilRemifentanil may increase the sedative activities of Ropinirole.Approved
RemoxiprideRemoxipride may increase the sedative activities of Ropinirole.Approved, Withdrawn
ReposalReposal may increase the sedative activities of Ropinirole.Approved
ReserpineReserpine may increase the sedative activities of Ropinirole.Approved, Investigational
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Ropinirole.Approved, Experimental, Investigational
RibostamycinRibostamycin may increase the sedative activities of Ropinirole.Approved, Investigational
RifampicinThe metabolism of Ropinirole can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Ropinirole can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Ropinirole can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Ropinirole can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleRiluzole may increase the sedative activities of Ropinirole.Approved, Investigational
RimexoloneThe metabolism of Ropinirole can be increased when combined with Rimexolone.Approved
RiociguatThe risk or severity of adverse effects can be increased when Ropinirole is combined with Riociguat.Approved
RisperidoneRisperidone may increase the sedative activities of Ropinirole.Approved, Investigational
RitanserinRitanserin may increase the sedative activities of Ropinirole.Investigational
RitonavirThe metabolism of Ropinirole can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanRizatriptan may increase the sedative activities of Ropinirole.Approved
RocuroniumRocuronium may increase the sedative activities of Ropinirole.Approved
RolipramRolipram may increase the sedative activities of Ropinirole.Investigational
RolitetracyclineRolitetracycline may increase the sedative activities of Ropinirole.Approved
RomifidineRomifidine may increase the sedative activities of Ropinirole.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Rotigotine.Approved
RP-5063RP-5063 may increase the sedative activities of Ropinirole.Investigational
RucaparibThe metabolism of Rucaparib can be decreased when combined with Ropinirole.Approved, Investigational
RufinamideRufinamide may increase the sedative activities of Ropinirole.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Sacubitril.Approved
SafinamideSafinamide may increase the sedative activities of Ropinirole.Approved, Investigational
SafrazineSafrazine may increase the sedative activities of Ropinirole.Withdrawn
SaquinavirThe metabolism of Ropinirole can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantSaredutant may increase the sedative activities of Ropinirole.Investigational
SarilumabThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineScopolamine may increase the sedative activities of Ropinirole.Approved, Investigational
SecobarbitalSecobarbital may increase the sedative activities of Ropinirole.Approved, Vet Approved
SelegilineSelegiline may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
SertindoleSertindole may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the sedative activities of Ropinirole.Approved
SevofluraneSevoflurane may increase the sedative activities of Ropinirole.Approved, Vet Approved
SibutramineSibutramine may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational, Withdrawn
SilodosinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Silodosin.Approved
SiltuximabThe serum concentration of Ropinirole can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ropinirole can be increased when it is combined with Simeprevir.Approved
SisomicinSisomicin may increase the sedative activities of Ropinirole.Investigational
Sodium oxybateSodium oxybate may increase the sedative activities of Ropinirole.Approved
SotalolThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Sotalol.Approved
SpironolactoneThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Spironolactone.Approved
St. John's WortSt. John's Wort may increase the sedative activities of Ropinirole.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Ropinirole can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Ropinirole is combined with Streptokinase.Approved, Investigational
StreptomycinStreptomycin may increase the sedative activities of Ropinirole.Approved, Vet Approved
StyramateStyramate may increase the sedative activities of Ropinirole.Experimental
SuccinylcholineSuccinylcholine may increase the sedative activities of Ropinirole.Approved
SufentanilSufentanil may increase the sedative activities of Ropinirole.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ropinirole.Approved, Investigational
SulthiameSulthiame may increase the sedative activities of Ropinirole.Experimental
SultoprideSultopride may increase the sedative activities of Ropinirole.Experimental
SumatriptanSumatriptan may increase the sedative activities of Ropinirole.Approved, Investigational
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved
TacrineThe metabolism of Tacrine can be decreased when combined with Ropinirole.Investigational, Withdrawn
TafenoquineThe metabolism of Tafenoquine can be decreased when combined with Ropinirole.Approved, Investigational
TalbutalTalbutal may increase the sedative activities of Ropinirole.Approved, Illicit
TalinololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Talinolol.Investigational
TalopramTalopram may increase the sedative activities of Ropinirole.Experimental
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ropinirole resulting in a loss in efficacy.Approved
TamsulosinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Tamsulosin.Approved, Investigational
TandospironeTandospirone may increase the sedative activities of Ropinirole.Investigational
TapentadolTapentadol may increase the sedative activities of Ropinirole.Approved
TasimelteonTasimelteon may increase the sedative activities of Ropinirole.Approved, Investigational
TegafurThe metabolism of Tegafur can be decreased when combined with Ropinirole.Approved, Investigational
TelaprevirThe metabolism of Ropinirole can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ropinirole can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Telmisartan.Approved, Investigational
TemazepamTemazepam may increase the sedative activities of Ropinirole.Approved, Investigational
TerazosinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ropinirole.Approved, Investigational, Vet Approved
TergurideTerguride may increase the hypertensive and vasoconstricting activities of Ropinirole.Experimental
TeriflunomideThe serum concentration of Ropinirole can be decreased when it is combined with Teriflunomide.Approved
TertatololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Tertatolol.Experimental
TetracyclineTetracycline may increase the sedative activities of Ropinirole.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the sedative activities of Ropinirole.Investigational
TetrazepamTetrazepam may increase the sedative activities of Ropinirole.Experimental
TetrodotoxinTetrodotoxin may increase the sedative activities of Ropinirole.Investigational
ThalidomideThalidomide may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Ropinirole.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ropinirole.Approved
ThiamylalThiamylal may increase the sedative activities of Ropinirole.Approved, Vet Approved
ThiazinamThiazinam may increase the sedative activities of Ropinirole.Experimental
ThiethylperazineThiethylperazine may increase the sedative activities of Ropinirole.Withdrawn
ThiocolchicosideThiocolchicoside may increase the sedative activities of Ropinirole.Approved, Investigational
ThiopentalThiopental may increase the sedative activities of Ropinirole.Approved, Vet Approved
ThiopropazateThiopropazate may increase the sedative activities of Ropinirole.Experimental
ThioproperazineThioproperazine may increase the sedative activities of Ropinirole.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ropinirole.Approved, Withdrawn
ThiothixeneThiothixene may increase the sedative activities of Ropinirole.Approved
TiagabineTiagabine may increase the sedative activities of Ropinirole.Approved, Investigational
TianeptineTianeptine may increase the sedative activities of Ropinirole.Approved, Investigational
TiaprideTiapride may increase the sedative activities of Ropinirole.Approved, Investigational
TiboloneTibolone may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TigecyclineTigecycline may increase the sedative activities of Ropinirole.Approved
TiletamineTiletamine may increase the sedative activities of Ropinirole.Vet Approved
TilidineTilidine may increase the sedative activities of Ropinirole.Experimental
TimololThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Timolol.Approved
TipranavirThe metabolism of Ropinirole can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the sedative activities of Ropinirole.Approved, Investigational
TobramycinTobramycin may increase the sedative activities of Ropinirole.Approved, Investigational
TocilizumabThe serum concentration of Ropinirole can be decreased when it is combined with Tocilizumab.Approved
TofisopamTofisopam may increase the sedative activities of Ropinirole.Approved
TolazolineThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Tolazoline.Approved, Vet Approved
TolcaponeTolcapone may increase the sedative activities of Ropinirole.Approved, Withdrawn
ToloxatoneToloxatone may increase the sedative activities of Ropinirole.Approved
TolperisoneTolperisone may increase the sedative activities of Ropinirole.Approved, Investigational
TopiramateTopiramate may increase the sedative activities of Ropinirole.Approved
TorasemideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Torasemide.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Ropinirole.Approved, Investigational
TramadolTramadol may increase the sedative activities of Ropinirole.Approved, Investigational
TramiprosateTramiprosate may increase the sedative activities of Ropinirole.Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the sedative activities of Ropinirole.Approved, Investigational
TrazodoneTrazodone may increase the sedative activities of Ropinirole.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Ropinirole is combined with Triamterene.Approved
TriazolamTriazolam may increase the sedative activities of Ropinirole.Approved, Investigational
Tricaine methanesulfonateTricaine methanesulfonate may increase the sedative activities of Ropinirole.Vet Approved
TrichloroethyleneTrichloroethylene may increase the sedative activities of Ropinirole.Approved
TriclofosTriclofos may increase the sedative activities of Ropinirole.Withdrawn
TrifluoperazineTrifluoperazine may increase the sedative activities of Ropinirole.Approved, Investigational
TrifluperidolTrifluperidol may increase the sedative activities of Ropinirole.Experimental
TriflupromazineTriflupromazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
TrimazosinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Trimazosin.Experimental
TrimethadioneTrimethadione may increase the sedative activities of Ropinirole.Approved
TrimipramineTrimipramine may increase the sedative activities of Ropinirole.Approved
TriprolidineTriprolidine may increase the sedative activities of Ropinirole.Approved
TroleandomycinThe metabolism of Ropinirole can be decreased when combined with Troleandomycin.Approved
TubocurarineTubocurarine may increase the sedative activities of Ropinirole.Approved
UrapidilThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Urapidil.Investigational
VadimezanThe metabolism of Vadimezan can be decreased when combined with Ropinirole.Investigational
ValerianValerian may increase the sedative activities of Ropinirole.Approved, Experimental, Investigational
ValnoctamideValnoctamide may increase the sedative activities of Ropinirole.Investigational
Valproic AcidValproic Acid may increase the sedative activities of Ropinirole.Approved, Investigational
ValpromideValpromide may increase the sedative activities of Ropinirole.Experimental
ValsartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Valsartan.Approved, Investigational
VancomycinVancomycin may increase the sedative activities of Ropinirole.Approved
VecuroniumVecuronium may increase the sedative activities of Ropinirole.Approved
VemurafenibThe serum concentration of Ropinirole can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the sedative activities of Ropinirole.Approved
VeraliprideVeralipride may increase the sedative activities of Ropinirole.Experimental
VerapamilThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Verapamil.Approved
VigabatrinVigabatrin may increase the sedative activities of Ropinirole.Approved
VilazodoneVilazodone may increase the sedative activities of Ropinirole.Approved
ViloxazineViloxazine may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
VinbarbitalVinbarbital may increase the sedative activities of Ropinirole.Experimental
VinpocetineVinpocetine may increase the sedative activities of Ropinirole.Investigational
Vinyl etherVinyl ether may increase the sedative activities of Ropinirole.Experimental
VinylbitalVinylbital may increase the sedative activities of Ropinirole.Experimental
VoriconazoleThe metabolism of Ropinirole can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the sedative activities of Ropinirole.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Ropinirole.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Ropinirole.Approved
XP19986XP19986 may increase the sedative activities of Ropinirole.Investigational
XylazineXylazine may increase the sedative activities of Ropinirole.Vet Approved
ZafirlukastThe metabolism of Ropinirole can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonZaleplon may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
ZeranolZeranol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Vet Approved
ZiconotideZiconotide may increase the sedative activities of Ropinirole.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Ropinirole.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the sedative activities of Ropinirole.Withdrawn
ZiprasidoneZiprasidone may increase the sedative activities of Ropinirole.Approved
ZolazepamZolazepam may increase the sedative activities of Ropinirole.Vet Approved
ZolmitriptanZolmitriptan may increase the sedative activities of Ropinirole.Approved, Investigational
ZolpidemZolpidem may increase the sedative activities of Ropinirole.Approved
ZonisamideZonisamide may increase the sedative activities of Ropinirole.Approved, Investigational
ZopicloneZopiclone may increase the sedative activities of Ropinirole.Approved
ZotepineZotepine may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Ropinirole can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the sedative activities of Ropinirole.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US4452808
General References
Not Available
External Links
Human Metabolome Database
HMDB0014413
KEGG Drug
D08489
KEGG Compound
C07564
PubChem Compound
5095
PubChem Substance
46507918
ChemSpider
4916
BindingDB
50020680
ChEBI
8888
ChEMBL
CHEMBL589
Therapeutic Targets Database
DAP001515
PharmGKB
PA164749035
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Ropinirole
ATC Codes
N04BC04 — Ropinirole
AHFS Codes
  • 28:36.20.08 — Nonergot-derivative Dopamine Receptor Agonists
FDA label
Download (267 KB)
MSDS
Download (29.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailablePharmacokinetic Study2
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentParkinson's Disease (PD)1
1CompletedTreatmentRestless Legs Syndrome (RLS)2
1, 2RecruitingTreatmentParkinson's Disease (PD)1
1, 2RecruitingTreatmentIdiopathic hyperprolactinemic disorder / Prolactinoma1
2CompletedTreatmentCerebrovascular Accidents / Hemiparesis1
2CompletedTreatmentDependence, Cocaine1
2CompletedTreatmentFibromyalgia Syndrome, Primary1
2CompletedTreatmentParkinson's Disease (PD)1
2TerminatedTreatmentRestless Legs Syndrome (RLS)1
2Unknown StatusTreatmentUnverricht-Lundborg Syndrome1
3CompletedTreatmentIdiopathic Parkinson's Disease1
3CompletedTreatmentModerate to Severe Idiopathic Restless Legs Syndrome (RLS) / Restless Legs Syndrome (RLS)1
3CompletedTreatmentParkinson's Disease (PD)5
3CompletedTreatmentRestless Legs Syndrome (RLS)6
3Unknown StatusTreatmentParkinson's Disease (PD)1
4CompletedDiagnosticParkinson's Disease (PD)1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentParkinson's Disease (PD)1
4CompletedTreatmentRestless Legs Syndrome (RLS)1
4CompletedTreatmentSexual Dysfunctions1
4Enrolling by InvitationSupportive CareLiver Cirrhosis / Muscle Cramps1
4Unknown StatusTreatmentBipolar Disorder (BD) / Major Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableRestless Legs Syndrome (RLS)1
Not AvailableCompletedTreatmentParkinson's Disease (PD) / Restless Legs Syndrome (RLS)2
Not AvailableRecruitingNot AvailableAtypical Parkinson Disease / Corticobasal Degeneration / Gait, Frontal / Multiple System Atrophy (MSA) / Parkinson's Disease (PD) / Parkinsonian Disorders / Progressive Supranuclear Palsy (PSP)1

Pharmacoeconomics

Manufacturers
  • Smithkline beecham corp dba glaxosmithkline
  • Glaxosmithkline
  • Alembic ltd
  • Corepharma llc
  • Glenmark generics ltd
  • Huahai us inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Zydus pharmaceuticals usa inc
Packagers
  • Amerisource Health Services Corp.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bryant Ranch Prepack
  • Cadila Healthcare Ltd.
  • Cardinal Health
  • Corepharma LLC
  • GlaxoSmithKline Inc.
  • Glenmark Generics Ltd.
  • Heartland Repack Services LLC
  • Heritage Pharmaceuticals
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Rebel Distributors Corp.
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Vangard Labs Inc.
  • Wockhardt Ltd.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral1 mg
TabletOral2 mg
TabletOral5 mg
TabletOral3.0 mg
TabletOral4.0 mg
TabletOral0.25 mg
TabletOral0.5 mg
TabletOral1.0 mg
TabletOral2.0 mg
TabletOral5.0 mg
Tablet, film coated, extended releaseOral12 mg/1
Tablet, film coated, extended releaseOral2 mg/1
Tablet, film coated, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral6 mg/1
Tablet, film coated, extended releaseOral8 mg/1
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, film coatedOral.25 mg/1
Tablet, film coatedOral.5 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral3 mg/1
Tablet, film coatedOral4 mg/1
Tablet, film coatedOral5 mg/1
TabletOral3 mg/1
TabletOral4 mg/1
TabletOral5 mg/1
Tablet, coatedOral.25 mg/1
Tablet, coatedOral.5 mg/1
Tablet, coatedOral1 mg/1
Tablet, coatedOral2 mg/1
Tablet, coatedOral4 mg/1
Tablet, coatedOral5 mg/1
Prices
Unit descriptionCostUnit
Requip XL 12 mg 24 Hour tablet14.92USD tablet
Requip xl 12 mg tablet14.35USD tablet
Requip XL 8 mg 24 Hour tablet8.96USD tablet
Requip xl 6 mg tablet8.61USD tablet
Requip xl 8 mg tablet8.61USD tablet
Requip XL 4 mg 24 Hour tablet5.97USD tablet
Requip xl 4 mg tablet5.74USD tablet
Requip 5 mg Tablet3.87USD tablet
Requip 3 mg tablet3.41USD tablet
Requip 4 mg tablet3.41USD tablet
Requip 5 mg tablet3.41USD tablet
Requip 0.25 mg tablet3.29USD tablet
Requip 0.5 mg tablet3.29USD tablet
Requip 1 mg tablet3.29USD tablet
Requip 2 mg tablet3.29USD tablet
Requip xl 2 mg tablet2.87USD tablet
Ropinirole hcl 3 mg tablet2.65USD tablet
Ropinirole hcl 4 mg tablet2.65USD tablet
Ropinirole hcl 5 mg tablet2.65USD tablet
Ropinirole hcl 0.25 mg tablet2.55USD tablet
Ropinirole hcl 0.5 mg tablet2.55USD tablet
Ropinirole hcl 1 mg tablet2.55USD tablet
Ropinirole hcl 2 mg tablet2.55USD tablet
Co Ropinirole 5 mg Tablet1.8USD tablet
Pms-Ropinirole 5 mg Tablet1.8USD tablet
Ran-Ropinirole 5 mg Tablet1.8USD tablet
Ropinirole 5 mg Tablet1.8USD tablet
Requip 2 mg Tablet1.41USD tablet
Requip 1 mg Tablet1.28USD tablet
Co Ropinirole 2 mg Tablet0.65USD tablet
Pms-Ropinirole 2 mg Tablet0.65USD tablet
Ran-Ropinirole 2 mg Tablet0.65USD tablet
Ropinirole 2 mg Tablet0.65USD tablet
Co Ropinirole 1 mg Tablet0.59USD tablet
Pms-Ropinirole 1 mg Tablet0.59USD tablet
Ran-Ropinirole 1 mg Tablet0.59USD tablet
Ropinirole 1 mg Tablet0.59USD tablet
Requip 0.25 mg Tablet0.32USD tablet
Co Ropinirole 0.25 mg Tablet0.15USD tablet
Pms-Ropinirole 0.25 mg Tablet0.15USD tablet
Ran-Ropinirole 0.25 mg Tablet0.15USD tablet
Ropinirole 0.25 mg Tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5422123No1995-06-062012-06-06Us
US7927624No2001-12-022021-12-02Us
US8303986No2001-04-122021-04-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)243-250 °CNot Available
water solubility133 mg/mLNot Available
logP2.70ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.353 mg/mLALOGPS
logP3.16ALOGPS
logP3.06ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)13.24ChemAxon
pKa (Strongest Basic)10.17ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity81.43 m3·mol-1ChemAxon
Polarizability31.19 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9971
Caco-2 permeable+0.6087
P-glycoprotein substrateSubstrate0.7604
P-glycoprotein inhibitor IInhibitor0.5458
P-glycoprotein inhibitor IINon-inhibitor0.8641
Renal organic cation transporterNon-inhibitor0.602
CYP450 2C9 substrateNon-substrate0.8593
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6903
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6959
Ames testNon AMES toxic0.7302
CarcinogenicityNon-carcinogens0.905
BiodegradationNot ready biodegradable0.9966
Rat acute toxicity2.6400 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8959
hERG inhibition (predictor II)Non-inhibitor0.7066
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0190000000-7e072cf65f341641938c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-3960000000-47d2311adfeeacf4062d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-7900000000-0891c66db163729a5360
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-88c0fa3d93090a0d06c6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pb9-3590000000-8fb5fc766313ee6bbd9e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0k96-9400000000-f1b50dacd59a9bfe90b7

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolines
Direct Parent
Indolines
Alternative Parents
Phenethylamines / Aralkylamines / Trialkylamines / Secondary carboxylic acid amides / Lactams / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Dihydroindole / Phenethylamine / Aralkylamine / Benzenoid / Amino acid or derivatives / Carboxamide group / Lactam / Secondary carboxylic acid amide / Tertiary aliphatic amine / Tertiary amine
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amine, indolones (CHEBI:8888)

Targets

Details
1. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. de Mey C, Enterling D, Meineke I, Yeulet S: Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1991 Oct;32(4):483-8. [PubMed:1683559]
  3. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N: Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999 Aug 14;838(1-2):51-9. [PubMed:10446316]
  4. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  5. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  6. Matsukawa N, Maki M, Yasuhara T, Hara K, Yu G, Xu L, Kim KM, Morgan JC, Sethi KD, Borlongan CV: Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. Brain Res. 2007 Jul 30;1160:113-23. Epub 2007 May 26. [PubMed:17573046]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Details
7. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Details
8. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:38